A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8+ cells in locally advanced rectal cancer. (September 2021)
- Record Type:
- Journal Article
- Title:
- A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8+ cells in locally advanced rectal cancer. (September 2021)
- Main Title:
- A radiomic signature model to predict the chemoradiation-induced alteration in tumor-infiltrating CD8+ cells in locally advanced rectal cancer
- Authors:
- Jeon, Seung Hyuck
Lim, Yu Jin
Koh, Jaemoon
Chang, Won Ick
Kim, Sehui
Kim, Kyubo
Chie, Eui Kyu - Abstract:
- Highlights: This study incorporated radiomic features and immunohistochemistry of rectal cancer. The MRI-based radiomic signature predicted CD8 + TIL alterations after chemoradiation. Our results suggest the clinical utility of radiomics-immunophenotype modeling. Abstract: Background and purpose: Regarding the altered tumor immune status following cytotoxic treatment, this study aims to develop a radiomic signature to predict CD8 + tumor-infiltrating lymphocyte (TIL) density changes in chemoradiotherapy (CRT) of rectal cancer. Materials and methods: We used the magnetic resonance imaging (MRI) and immunohistochemistry data before and after neoadjuvant CRT. The discovery datasets consisted of pre-CRT dataset A1 ( n = 113), post-CRT datasets A2 ( n = 32; predominance of tumor) and A3 ( n = 20; pure fibrosis). The developed model was validated in dataset B ( n = 28). Thirty-eight radiomic features from T2-weighted MRI scans were incorporated into the least absolute shrinkage and selection operator method. Results: In pre-CRT dataset A1, the area under the receiver operating characteristic curve (AUC) values of radiomic score for predicting CD8 + TILs were 0.760 and 0.729 for training and validation subsets, respectively. A significant correlation was observed between the signature and CD8 + TIL density in the post-CRT dataset A2 (Pearson's R = −0.372, P = 0.036), whereas no association was found in dataset A3 (Pearson's R = −0.069, P = 0.77). The association was alsoHighlights: This study incorporated radiomic features and immunohistochemistry of rectal cancer. The MRI-based radiomic signature predicted CD8 + TIL alterations after chemoradiation. Our results suggest the clinical utility of radiomics-immunophenotype modeling. Abstract: Background and purpose: Regarding the altered tumor immune status following cytotoxic treatment, this study aims to develop a radiomic signature to predict CD8 + tumor-infiltrating lymphocyte (TIL) density changes in chemoradiotherapy (CRT) of rectal cancer. Materials and methods: We used the magnetic resonance imaging (MRI) and immunohistochemistry data before and after neoadjuvant CRT. The discovery datasets consisted of pre-CRT dataset A1 ( n = 113), post-CRT datasets A2 ( n = 32; predominance of tumor) and A3 ( n = 20; pure fibrosis). The developed model was validated in dataset B ( n = 28). Thirty-eight radiomic features from T2-weighted MRI scans were incorporated into the least absolute shrinkage and selection operator method. Results: In pre-CRT dataset A1, the area under the receiver operating characteristic curve (AUC) values of radiomic score for predicting CD8 + TILs were 0.760 and 0.729 for training and validation subsets, respectively. A significant correlation was observed between the signature and CD8 + TIL density in the post-CRT dataset A2 (Pearson's R = −0.372, P = 0.036), whereas no association was found in dataset A3 (Pearson's R = −0.069, P = 0.77). The association was also observed in the validation dataset B (Pearson's R = −0.374, P = 0.049). In dataset A2, the radiomic score difference predicted changes in CD8 + TIL density (AUC = 0.824). Conclusion: We established the MRI-derived radiomic signature for predicting CRT-induced alterations in CD8 + TILs. This study suggests the clinical utility of radiomics-immunophenotype modeling to evaluate tumor immune status following neoadjuvant chemoradiation in rectal cancer. … (more)
- Is Part Of:
- Radiotherapy and oncology. Volume 162(2021)
- Journal:
- Radiotherapy and oncology
- Issue:
- Volume 162(2021)
- Issue Display:
- Volume 162, Issue 2021 (2021)
- Year:
- 2021
- Volume:
- 162
- Issue:
- 2021
- Issue Sort Value:
- 2021-0162-2021-0000
- Page Start:
- 124
- Page End:
- 131
- Publication Date:
- 2021-09
- Subjects:
- Rectal neoplasms -- Radiomics -- CD8-positive T-lymphocytes -- Chemoradiotherapy -- Radiomic score -- Neoadjuvant therapy
Oncology -- Periodicals
Radiotherapy -- Periodicals
Tumors -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- radiotherapy -- Periodicals
Radiotherapy -- Periodicals
Radiothérapie -- Périodiques
Cancérologie -- Périodiques
Tumeurs -- Périodiques
Electronic journals
616.9940642 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01678140 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01678140 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01678140 ↗
http://www.estro.org/ ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/radiotherapy-and-oncology/ ↗ - DOI:
- 10.1016/j.radonc.2021.07.004 ↗
- Languages:
- English
- ISSNs:
- 0167-8140
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7240.790000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19592.xml